Resident.
Consultant in Maternal-Fetal Medicine, Third Department of Obstetrics and Gynaecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Obstet Gynecol Surv. 2023 May;78(5):287-301. doi: 10.1097/OGX.0000000000001133.
Recurrent pregnancy loss (RPL) is one of the most frustrating clinical entities in reproductive medicine requiring not only diagnostic investigation and therapeutic intervention, but also evaluation of the risk for recurrence.
The aim of this study was to review and compare the most recently published major guidelines on investigation and management of RPL.
A descriptive review of guidelines from the Royal College of Obstetricians and Gynaecologists, the European Society of Human Reproduction and Embryology, the American Society for Reproductive Medicine, the French College of Gynecologists and Obstetricians, and the German, Austrian, and Swiss Society of Gynecology and Obstetrics on RPL was carried out.
There is consensus among the reviewed guidelines that the mainstays of RPL investigation are a detailed personal history and screening for antiphospholipid syndrome and anatomical abnormalities of the uterus. In contrast, inherited thrombophilias, vaginal infections, and immunological and male factors of infertility are not recommended as part of a routine RPL investigation. Several differences exist regarding the necessity of the cytogenetic analysis of the products of conception, parental peripheral blood karyotyping, ovarian reserve testing, screening for thyroid disorders, diabetes or hyperhomocysteinemia, measurement of prolactin levels, and performing endometrial biopsy. Regarding the management of RPL, low-dose aspirin plus heparin is indicated for the treatment of antiphospholipid syndrome and levothyroxine for overt hypothyroidism. Genetic counseling is required in case of abnormal parental karyotype. The Royal College of Obstetricians and Gynaecologists, the European Society of Human Reproduction and Embryology, and the French College of Gynecologists and Obstetricians guidelines provide recommendations that are similar on the management of cervical insufficiency based on the previous reproductive history. However, there is no common pathway regarding the management of subclinical hypothyroidism and the surgical repair of congenital and acquired uterine anomalies. Use of heparin for inherited thrombophilias and immunotherapy and anticoagulants for unexplained RPL are not recommended, although progesterone supplementation is suggested by the American Society for Reproductive Medicine and the German, Austrian, and Swiss Society of Gynecology and Obstetrics.
Recurrent pregnancy loss is a devastating condition for couples. Thus, it seems of paramount importance to develop consistent international practice protocols for cost-effective investigation and management of this early pregnancy complication, with the aim to improve live birth rates.
复发性流产(RPL)是生殖医学中最令人沮丧的临床实体之一,不仅需要进行诊断性检查和治疗干预,还需要评估复发风险。
本研究旨在回顾和比较最近发表的关于 RPL 调查和管理的主要指南。
对皇家妇产科医师学院、欧洲人类生殖与胚胎学会、美国生殖医学学会、法国妇产科医师学院以及德国、奥地利和瑞士妇科和产科协会关于 RPL 的指南进行了描述性回顾。
在所审查的指南中,人们普遍认为 RPL 调查的主要依据是详细的个人病史和抗磷脂综合征以及子宫解剖异常的筛查。相比之下,遗传性血栓形成倾向、阴道感染以及免疫和男性不孕因素不建议作为常规 RPL 调查的一部分。关于妊娠产物的细胞遗传学分析、父母外周血染色体核型分析、卵巢储备测试、甲状腺疾病、糖尿病或高同型半胱氨酸血症筛查、催乳素水平测量以及进行子宫内膜活检的必要性,存在一些差异。关于 RPL 的治疗,低剂量阿司匹林加肝素适用于治疗抗磷脂综合征,左甲状腺素适用于显性甲状腺功能减退。如果父母染色体核型异常,则需要进行遗传咨询。皇家妇产科医师学院、欧洲人类生殖与胚胎学会和法国妇产科医师学院的指南根据既往生殖史提供了类似的关于宫颈机能不全管理的建议。然而,对于亚临床甲状腺功能减退和先天性及获得性子宫畸形的手术修复,没有共同的治疗途径。对于遗传性血栓形成倾向,肝素的使用以及不明原因的 RPL 的免疫治疗和抗凝剂的使用不被推荐,尽管美国生殖医学学会和德国、奥地利和瑞士妇科和产科协会建议补充孕激素。
复发性流产对夫妇来说是一种毁灭性的疾病。因此,制定一致的国际实践方案,以具有成本效益的方式调查和管理这种早期妊娠并发症,以提高活产率,这似乎至关重要。